Experts argue for payors to make better use of genomic testing for cancer patients

December 1, 2017 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

(Medical Xpress)—Harold Varmus, former National Cancer Institute Director and Rebecca Eisenberg a professor at the University of Michigan Law School have published a Policy Forum paper in the journal Science arguing for better use of genomic testing for cancer patients. They suggest that government and private payors (insurance companies) make better use of databases and registries to figure out if genomic testing can be used for personalized treatment of cancer patients. They suggest doing so would lead to improved outcomes.

In their paper, Varmus and Eisenberg note that some research firms and academic institutions offer genetic sequencing for , but it is mostly done for research purposes. Insurance companies in the U.S., they claim, will not pay for such work. This, they note has led to a catch-22 of sorts. Much more genetic data is needed for the various types of cancer in order to conduct research that can lead to individualized treatments for patients. More data is also needed by the insurance companies to make coverage decisions. But that data cannot be obtained without the involvement of large numbers of patients, which would require insurance companies to foot much of the bill. Varmus and Eisenberg also note that the U.S. FDA has been approving cancer drugs at an accelerated pace, which has been blurring the lines between research and care, further complicating decisions regarding use of .

To address the problem, the authors suggest insurance companies and researchers both make better use of a mechanism called "coverage with evidence development" (CED)—a model in which multiple private insurers cover experimental clinical services. They note that the Centers for Medicare and Medicaid Services already uses the mechanism, and at times, even approve payments for new technology as part of it. They note also that it has been tried with Medicare as part of a program aimed at treatments involving lung volume reduction surgery. Making better use of CED, they further contend, would encourage patients to play a bigger role in adding their data to registries.

Varmus and Eisenberg also argue that need to take a closer look at the actual costs associated with , which they claim would be just 1 percent of cancer care bills—for that proportionally small amount of money, they could conceivably improve the outcomes for many patients.

Explore further: New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

More information: Rebecca Eisenberg et al. Insurance for broad genomic tests in oncology, Science (2017). DOI: 10.1126/science.aao6708

Summary
Tests based on DNA sequencing methods are redefining diagnostic categories in oncology and providing a rational basis for the development and use of new cancer therapies, especially the many drugs targeted against mutant proteins that drive malignant growth. The medical and economic value of identifying specific genetic abnormalities in cancers has been established by the evidence-based use of targeted drugs and immunotherapies in cancer patients (see the figure for an example). For some cancer therapies, the U.S. Food and Drug Administration (FDA)–approved label calls for the use of a companion diagnostic test for the presence or absence of certain genetic changes before initiating treatment. Most recently, the FDA approved the use of the immunotherapeutic pembrolizumab for treatment of tumors that show a defect in DNA repair called microsatellite instability, irrespective of the tissue of origin; although an FDA-approved test for microsatellite instability is not yet available, many clinical laboratories are using assays for the relevant biomarkers.

Related Stories

New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

October 19, 2017
The results of a national cancer survey find a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were ...

Delays for melanoma surgeries linked to insurance type

October 4, 2017
A retrospective review of several thousand melanoma cases in North Carolina found that Medicaid patients were more likely to experience surgical treatment delays than patients with private insurance, according to a study ...

Does health insurance status affect childhood cancer survival?

September 11, 2017
A new study examines whether insurance status may affect survival in children diagnosed with cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest largely similar ...

ACA Medicaid expansion cut disparities in cancer care for minorities, poor

September 26, 2017
States that fully expanded their Medicaid programs under the Affordable Care Act cut their rates of uninsured cancer patients by more than half between 2011 and 2014. Black patients and those living in the highest poverty ...

CONNECT registry shows only 9 percent compliance with genetic testing guidelines for AML

June 5, 2017
Guidelines by the National Comprehensive Cancer Network (NCCN) recommend testing for seven known genetic changes in patients with Acute Myeloid Leukemia (AML). A study presented today at the American Society for Clinical ...

97 percent of insurance denials in pediatric proton patients overturned on appeal

August 7, 2017
Insurance companies end up covering proton therapy treatment for pediatric cancer patients in 97 percent of the cases they originally deny once those decisions are appealed. Researchers from the Perelman School of Medicine ...

Recommended for you

Add broken DNA repair to the list of inherited colorectal cancer risk factors

February 23, 2018
An analysis of nearly 3,800 colorectal cancer patients—the largest germline risk study for this cancer to date—reveals opportunities for improved risk screening and, possibly, treatment.

Team identifies genetic defect that may cause rare movement disorder

February 22, 2018
A Massachusetts General Hospital (MGH)-led research team has found that a defect in transcription of the TAF1 gene may be the cause of X-linked dystonia parkinsonism (XDP), a rare and severe neurodegenerative disease. The ...

Defects on regulators of disease-causing proteins can cause neurological disease

February 22, 2018
When the protein Ataxin1 accumulates in neurons it causes a neurological condition called spinocerebellar ataxia type 1 (SCA1), a disease characterized by progressive problems with balance. Ataxin1 accumulates because of ...

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.